During the last session, Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares were 2.95 million, with the beta value of the company hitting 2.83. At the
During the recent session, Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares were 1.14 million, with the beta value of the company hitting 2.83. At the
In the last trading session, 3.51 million shares of the Black Diamond Therapeutics Inc (NASDAQ:BDTX) were traded, and its beta was 2.78. Most recently the
In the last trading session, 5.9 million shares of the Black Diamond Therapeutics Inc (NASDAQ:BDTX) were traded, and its beta was 2.75. Most recently the
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares stood at 22.06 million during the last session, with the company’s beta value hitting 2.79. At the close
In the latest trading session, 83.23 million Black Diamond Therapeutics Inc (NASDAQ:BDTX) shares changed hands as the company’s beta touched 2.79. With the company’s most
During the last session, Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares were 0.36 million, with the beta value of the company hitting 2.77. At the
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares stood at 0.36 million during the last session, with the company’s beta value hitting 2.53. At the close
In last trading session, Black Diamond Therapeutics Inc (NASDAQ:BDTX) saw 0.39 million shares changing hands with its beta currently measuring 2.49. Company’s recent per share
During the last session, Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares were 0.43 million, with the beta value of the company hitting 2.49. At the
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
